Bioengineering Solutions Inc.

Email: nhallab@bioengineeringsolutions.com    Tel: 312-259-1802

Well over 600,000 total joint arthroplasties (TJAs) are performed yearly in the United States alone. For most patients, short and intermediate term (2-7 year) results are satisfactory. Because of this success, the use of implants is growing in both older patient populations and in younger patients. This rising use will increase the total number of people that will experience problems expected to occur in a relatively small percentage (<7%) of recipients, such as infection and idiopathic “premature” implant failure (<10 years).

Patients with TJA’s are exposed to billions of metal, polyethylene, and/or ceramic particles generated by implant (wear) degradation in vivo, which accumulate adjacent to the implant and bone, and induce inflammatory cell/tissue reactions. Long-term biocompatibility or performance of current implants is largely determined by the degradation products of implants produced from this mechanical wear and electrochemical corrosion